Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers December 15, 2017
Pharmacy Choice - Pharmacy News - December 15, 2017

Pharmacy News

Today's Pharmaceutical and Pharmacy News
Daily News Topic:

FDA News
12/15/17 - FDA approves â??Abilifyâ?? trackable pill from Otsuka
US regulators have approved the first pill that can be digitally tracked through the body. The Abilify MyCite aripiprazole tablets- for treating schizophrenia and manic episodes-have an ingestible sensor embedded inside them that records that the medication has been taken. Mitchell Mathis, from the Food and Drug Administration, said:â?? Being able
12/15/17 - FDA expands labeling on 3D breast exams
A type of breast imaging used by Tidelands Health has been approved by the FDA as the only mammography exam superior to standard 2 D mammography for routine cancer screenings of women with dense breasts. Hologicâ?? s Genius 3 D Mammography exam is offered at all Tidelands Health mammography locations. The Genius 3 D exam is the only mammogram clini
12/15/17 - Masimo Announces FDA Clearance and Worldwide Release of NomoLineâ?¢ Capnography Sampling Lines
By a News Reporter-Staff News Editor at Health& Medicine Week-- Masimo announced FDA clearance and U.S. release of the full family of NomoLineâ?¢ capnography sampling lines. NomoLine sampling lines are available in more than 40 configurations of airway adapter sets and cannulas for use in a variety of clinical scenarios, including for intubated and
12/15/17 - Pfizer Announces FDA Approval of XELJANZ® (tofacitinib) and XELJANZ® XR for the Treatment of Active Psoriatic Arthritis
Pfizer Inc. announced today that the United States Food and Drug Administration has approved XELJANZ ® 5 mg twice daily and XELJANZ ® XR extended release 11 mg once daily for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic d
12/14/17 - Allergan Receives FDA Clearance for the CoolSculpting Treatment to Improve Appearance of Lax Tissue in the Double Chin
DUBLIN- Allergan plc today announced that the CoolSculpting treatment is the first and only non-surgical fat reduction technology to be FDA- cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. 'In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini ap
12/14/17 - Chemence Medical Receives FDA Clearance for Exofin Fusion® Skin Closure System
Chemence Medical, Inc., a manufacturer and distributor of adhesive-based medical devices, announced it received Food and Drug Administration clearance to market and sell Exofin Fusion ®, a new skin closure system for medium to large wounds. Exofin Fusion combines a self-adhering flexible mesh strip, mesh anchors and a fast-curing 2- octyl cyanoacr

Chain Drug Review
Chain Drug Review Magazine Chain Drug Review, established in 1978 and published 21 times a year, is recognized as the premier news publication serving the entire chain drug store industry.
Featured Article from Chain Drug Review:
AWP suit settlement appealed
The National Association of Chain Drug Stores has appealed a U.S. District Court’s approval of settlements in the First DataBank Inc. and Medi-Span Inc. lawsuit. »read more

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement